Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2017-02-21 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is a 'Year End Report' for the period January-December 2016. It contains comprehensive financial data, including income statements, loss per share, and detailed management commentary on business operations, research projects, and future outlook. It is a substantive financial report covering a period shorter than a full fiscal year (in terms of the quarterly breakdown) or a full fiscal year report, fitting the definition of an Interim/Quarterly Report (IR) or Annual Report (10-K). Given the title 'Year End Report' and the inclusion of both Q4 and full-year 2016 financial results, it is classified as an Interim/Quarterly Report (IR) as it provides the detailed financial performance for the period. FY 2016
2017-02-21 English
NeuroVive’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells
Regulatory Filings Classification · 1% confidence The document is a press release dated February 2, 2017, announcing the presentation of preclinical data regarding new sanglifehrin-based compounds at the EASL HCC Summit. It details scientific findings, quotes the Chief Medical Officer, and includes standard company boilerplate and contact information. Crucially, the final paragraph states: "This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication... on February 2, 2017." This structure strongly indicates a general regulatory announcement or press release regarding company news, rather than a formal financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or DVA). Since it is a general announcement mandated by regulation (EU Market Abuse Regulation) that doesn't fit the specific categories like ER (Earnings Release), CT (Call Transcript), or DIV (Dividend Notice), the most appropriate fallback category is Regulatory Filings (RNS). The document length (5864 chars) is substantial enough that it is the primary announcement itself, not just a brief notice of publication (RPA).
2017-02-02 English
NeuroVives nya generation av sanglifehrin-baserade substanser uppvisar starkt hämmande effekt på humana levercancerceller
Earnings Release Classification · 1% confidence The document is a press release dated February 2, 2017, announcing preclinical data regarding new sanglifehrin-based substances showing strong inhibitory effects on human liver cancer cells (HCC). It details scientific findings, compares them to existing drugs (sorafenib), mentions the results will be presented at a scientific conference (EASL HCC Summit), and includes standard company boilerplate and contact information. This format—a formal announcement of scientific/clinical progress, often preceding a full regulatory filing or earnings report—is characteristic of an Earnings Release (ER) or a general press release detailing operational/research milestones. Since it focuses on presenting new scientific data and results, it aligns best with the 'Earnings Release' (ER) category, which often includes key operational/research highlights, even if it's not strictly quarterly financial results. It is not a full 10-K, an Audit Report (AR), a Call Transcript (CT), or a specific regulatory filing like DIRS or DIV. Given the context of presenting new data/results, ER is the most appropriate fit among the provided options. FY 2017
2017-02-02 Swedish
NeuroVive redirects research resources from Asian subsidiary to parent
Capital/Financing Update Classification · 1% confidence The document announces a strategic corporate restructuring: redirecting research resources from an Asian subsidiary to the parent company and selling the subsidiary's operations. It details the financial implications (receiving 5 million SEK) and the reacquisition of licensing rights for key assets (NeuroSTAT). This type of announcement, which involves changes in corporate structure, asset transfer, and strategic focus, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were purely a mandatory disclosure without significant financial/structural detail. However, since it directly concerns the restructuring of operations and the transfer of assets/cash flow related to the corporate structure, 'CAP' is a strong fit, as it relates to capital structure changes and resource allocation. Given the context of a strategic business decision impacting assets and operations, 'CAP' (Capital/Financing Update) is the most appropriate specific category over the general 'RNS'. The document is a direct announcement, not a report itself, but it details a significant corporate action.
2017-01-25 English
NeuroVive omfördelar forskningsresurser från asiatiskt dotterbolag till moderbolaget
M&A Activity Classification · 1% confidence The document is a press release dated January 25, 2017, announcing a strategic restructuring: the reallocation of research resources from an Asian subsidiary to the parent company and the sale of the Taiwan-based subsidiary's operations. It details financial implications (receiving SEK 5 million) and changes in ownership structure for another subsidiary. The final paragraph explicitly states: "Denna information är sådan information som NeuroVive Pharmaceutical AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation). This mandatory disclosure, which is not a full financial report (like 10-K or IR) but a specific corporate action announcement, fits best under the general 'Regulatory Filings' category (RNS) as it is a required public disclosure under EU regulation, or potentially a Capital/Financing Update (CAP) due to the sale/restructuring, but RNS is the most appropriate catch-all for mandatory regulatory announcements that aren't standard periodic reports or specific events like dividends or director dealings. Given the nature of mandatory disclosure under MAR, RNS is the most fitting classification.
2017-01-25 Swedish
NeuroVive signs mitochondrial medicine research agreement with US key opinion leader
Regulatory Filings Classification · 1% confidence The document is a press release dated January 23, 2017, announcing a preclinical collaboration agreement between NeuroVive and the Children's Hospital of Philadelphia (CHOP) regarding the NVP015 compound. It details the nature of the research, provides background on the key opinion leader (Dr. Falk), and includes standard company boilerplate information and contact details. The final paragraph states: "This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication...". This structure is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, IR, ER, or DIV). Since it is a general announcement mandated by regulation (EU Market Abuse Regulation) and doesn't fit the other specific categories (like M&A, Capital Change, or Director's Dealing), the most appropriate fallback category is Regulatory Filings (RNS).
2017-01-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.